Opus Genetics, Inc.

NasdaqCM:IRD Stock Report

Market Cap: US$207.6m

Opus Genetics Valuation

Is IRD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of IRD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: IRD ($3.01) is trading below our estimate of future cash flow value ($71.29)

Significantly Below Future Cash Flow Value: IRD is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IRD?

Key metric: As IRD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IRD. This is calculated by dividing IRD's market cap by their current revenue.
What is IRD's PS Ratio?
PS Ratio14.2x
SalesUS$14.63m
Market CapUS$207.58m

Price to Sales Ratio vs Peers

How does IRD's PS Ratio compare to its peers?

The above table shows the PS ratio for IRD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.1x
VYGR Voyager Therapeutics
6.5x12.53%US$204.6m
ALEC Alector
3.1x-10.33%US$213.9m
ARCT Arcturus Therapeutics Holdings
2.2x37.17%US$215.1m
SGMO Sangamo Therapeutics
4.5x42.73%US$148.7m
IRD Opus Genetics
14.2x57.36%US$207.6m

Price-To-Sales vs Peers: IRD is expensive based on its Price-To-Sales Ratio (14.2x) compared to the peer average (7.5x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does IRD's PS Ratio compare vs other companies in the US Biotechs Industry?

123 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
3x-0.73%US$29.52b
BMRN BioMarin Pharmaceutical
3.6x6.55%US$11.17b
PTCT PTC Therapeutics
3.4x1.30%US$6.00b
ALKS Alkermes
3.8x8.96%US$5.76b
IRD 14.2xIndustry Avg. 11.2xNo. of Companies123PS01632486480+
123 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IRD is expensive based on its Price-To-Sales Ratio (14.2x) compared to the US Biotechs industry average (11.2x).

Price to Sales Ratio vs Fair Ratio

What is IRD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IRD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.2x
Fair PS Ratio2.4x

Price-To-Sales vs Fair Ratio: IRD is expensive based on its Price-To-Sales Ratio (14.2x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IRD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.01
US$7.73
+156.72%
13.62%US$9.00US$6.00n/a11
Feb ’27US$2.31
US$7.73
+234.51%
13.62%US$9.00US$6.00n/a11
Jan ’27US$2.01
US$7.80
+288.06%
13.81%US$9.00US$6.00n/a10
Dec ’26US$2.00
US$7.67
+283.33%
13.75%US$9.00US$6.00n/a9
Nov ’26US$2.30
US$7.29
+216.77%
20.38%US$9.00US$5.00n/a7
Oct ’26US$1.80
US$6.25
+247.22%
17.44%US$8.00US$5.00n/a4
Sep ’26US$1.22
US$6.00
+391.80%
20.41%US$8.00US$5.00n/a4
Aug ’26US$1.07
US$6.00
+460.75%
20.41%US$8.00US$5.00n/a4
Jul ’26US$0.94
US$6.00
+538.37%
20.41%US$8.00US$5.00n/a4
Jun ’26US$0.99
US$7.33
+637.39%
12.86%US$8.00US$6.00n/a3
May ’26US$0.94
US$7.33
+681.80%
12.86%US$8.00US$6.00n/a3
Apr ’26US$0.91
US$10.33
+1,035.53%
31.93%US$15.00US$8.00n/a3
Mar ’26US$1.03
US$10.50
+919.42%
25.64%US$15.00US$8.00n/a4
Feb ’26US$1.11
US$10.50
+845.95%
25.64%US$15.00US$8.00US$2.314
Jan ’26US$1.19
US$10.50
+782.35%
25.64%US$15.00US$8.00US$2.014
Dec ’25US$1.11
US$10.50
+845.95%
25.64%US$15.00US$8.00US$2.004
Nov ’25US$1.18
US$12.00
+916.95%
18.00%US$15.00US$10.00US$2.303
Oct ’25US$1.26
US$16.75
+1,229.37%
20.41%US$20.00US$11.00US$1.804
Sep ’25US$1.24
US$16.75
+1,250.81%
20.41%US$20.00US$11.00US$1.224
Aug ’25US$1.88
US$19.33
+928.37%
4.88%US$20.00US$18.00US$1.073
Jul ’25US$1.59
US$19.33
+1,115.93%
4.88%US$20.00US$18.00US$0.943
Jun ’25US$1.68
US$19.33
+1,050.79%
4.88%US$20.00US$18.00US$0.993
May ’25US$1.64
US$19.50
+1,089.02%
11.18%US$22.00US$16.00US$0.944
Apr ’25US$2.23
US$19.50
+774.44%
11.18%US$22.00US$16.00US$0.914
Mar ’25US$2.53
US$20.50
+710.28%
14.43%US$24.00US$16.00US$1.034
Feb ’25US$2.73
US$20.50
+650.92%
14.43%US$24.00US$16.00US$1.114
US$7.73
Fair Value
61.0% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/08 10:25
End of Day Share Price 2026/02/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Opus Genetics, Inc. is covered by 10 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Madison Wynne El-SaadiB. Riley Securities, Inc.
Kumaraguru RajaBrookline Capital Markets